"A study from Exact Sciences Corp. Nasdaq EXAS httpstudio.financialcontent.comprnewsPageQuoteTickerEXAS and Mayo Clinic released today by the American Association of Cancer Research AACR shows promise for the development of a bloodbased lung cancer test. Researchers conducted a multiround study of nearly  patients which demonstrated high accuracy for detecting lung cancer at all stages. These results reveal an opportunity to detect lung cancer from a simple blood draw said Kevin Conroy chairman and CEO of Exact Sciences. Our collaboration with Mayo Clinic is efficiently identifying biomarkers for additional cancer applications on the same technology platform as Cologuard. AACR released an abstract of the study today ahead of the presentation of the results on April   during the AACR  annual meeting. The findings from the study of  patients  controls and  cancers demonstrate that biomarkers in plasma achieved high accuracy for all types and stages of lung cancer. Using two independent regression modeling approaches a panel of four novel methylated DNA markers demonstrated a sensitivity of  percent at a specificity of  percent. More studies are needed to corroborate accuracy however this plasma DNA test approach appears to be a promising new method and may serve as a rational followup to the common findings of lung nodules on CT scanning and may have application in screening for lung cancer said David E. Midthun M.D. a pulmonologist at Mayo Clinic. Lung cancer is the leading cause of cancer mortality resulting in . million deaths globally and more than  deaths in the United States every year.  Most symptoms present in the late stages of the disease when the survival rate is only four percent. Early detection of lung cancer offers the opportunity to reduce mortality. Lung cancer screening is approved for smokers using chest CT scanning.  This approach has a sensitivity for lung cancer above  percent but its specificity may fall below  percent a false positive rate of more than  percent because indeterminate lung nodules are so common. Evaluation of these falsepositives leads to unnecessary costly and potentially harmful procedures. A bloodbased test may help guide next steps after a scan reveals an indeterminate nodule Mr. Conroy said. For example a positive blood test might suggest the need for a biopsy or surgery. In contrast a negative test might suggest a less aggressive approach. Such a test could offer the opportunity to significantly improve health outcomes and reduce the financial impact on the health care system.  The abstract is available here http A poster presentation of the findings will take place Sunday April   from  p.m. to  p.m. EDT at the Walter E. Washington Convention Center in Washington D.C. Halls AC Poster Section .   About Exact Sciences Corp.  Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive molecular screening technology for the detection of colorectal cancer. For more information please visit the companys website at  http follow Exact Sciences on Twitter ExactSciences or find Exact Sciences on Facebook. Safe Harbor Statement This news release contains forwardlooking statements within the meaning of Section A of the Securities Act of  as amended and Section E of the Securities Exchange Act of  as amended that are intended to be covered by the safe harbor created by those sections. Forwardlooking statements which are based on certain assumptions and describe our future plans strategies and expectations can generally be identified by the use of forwardlooking terms such as believe expect may will should could seek intend plan estimate anticipate or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies prospects financial condition operations costs plans and objectives are forwardlooking statements. Examples of forwardlooking statements include among others statements we make regarding expected future operating results anticipated results of our sales and marketing efforts expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forwardlooking statements are neither historical facts nor assurances of future performance. Instead they are based only on our current beliefs expectations and assumptions regarding the future of our business future plans and strategies projections anticipated events and trends the economy and other future conditions. Because forwardlooking statements relate to the future they are subject to inherent uncertainties risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forwardlooking statements. Therefore you should not rely on any of these forwardlooking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forwardlooking statements include among others the following our ability to successfully and profitably market our products and services the acceptance of our products and services by patients and healthcare providers our ability to meet demand for our products and services the willingness of health insurance companies and other payers to cover Cologuard and reimburse us for our performance of the Cologuard test the amount and nature of competition from other cancer screening products and services the effects of the adoption modification or repeal of any healthcare reform law rule order interpretation or policy the effects of changes in healthcare pricing coverage and reimbursement recommendations guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force the American Cancer Society and the National Committee for Quality Assurance regarding cancer screening or our products and services our ability to successfully develop new products and services our success establishing and maintaining collaborative licensing and supplier arrangements our ability to maintain regulatory approvals and comply with applicable regulations and the other risks and uncertainties described in the Risk Factors and in Managements Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form K and our subsequently filed Quarterly Reports on Form Q. We undertake no obligation to publicly update any forwardlooking statement whether written or oral that may be made from time to time whether as a result of new information future developments or otherwise."